Funds will enable the completion of the ongoing Phase 2a clinical trial growing ectopic livers for patients with end stage liver disease and advance LyGenesis’s pipeline of cell therapies

PITTSBURGH, Oct. 24, 2023 — LyGenesis, a clinical-stage biotechnology company developing cell therapies for patients with end stage liver disease, type 1 diabetes, end stage renal disease, and aging announced it has raised more than $19M in a Series A-2 financing round led by Prime Movers Lab, investors in breakthrough scientific startups, with follow-on funding from Juvenescence. This funding round will enable LyGenesis to complete its Phase 2a clinical trial (ClinicalTrials.gov Identifier: NCT04496479) and advance its pipeline of cell therapies.

“LyGenesis’s regenerative cell therapies have the potential to transform the lives of patients who are either medically ineligible for an organ transplant or are awaiting an organ to become available. Using lymph nodes as bioreactors to grow ectopic organs is the type of platform technology that could revolutionize the treatment of multiple diseases and beneficially affect millions of lives,” said Justin Briggs, Biologist and Partner at Prime Movers Lab, who will be joining LyGenesis’s Board of Directors.

“We’re delighted to continue our support for LyGenesis on its mission to restore the function of failing vital organs. By combining allogeneic cells from donated but discarded organs with a cost effective manufacturing process and engrafting their cell therapies using a low risk outpatient endoscopic ultrasound procedure, LyGenesis represents a truly remarkable opportunity,” said Richard Marshall, Chief Executive Officer of Juvenescence. The Series A-2 financing was also supported by Juvenescence and other investors.

ABOUT LYG-LIV-001 CELL THERAPY

LYG-LIV-001 is LyGenesis’s allogeneic cell therapy regulated by the FDA as a Section 351 Human Cellular Therapy/Product (HCT/P). This biologic therapy is created starting from donated livers, which are processed under Current Good Manufacturing Practice through a multi-step procedure to carefully isolate and suspend the hepatocytes in a solution to ready them for engraftment into that patient’s mesenteric lymph nodes using an endoscopic ultrasound. The lymph node then acts an as in vivo bioreactor, helping the hepatocytes to engraft, proliferate, and generate functional ectopic liver tissue. Unlike CRISPR or CAR-T therapies, LyGenesis’s LYG-LIV-001 does not genetically engineer its cellular therapy, reducing the time and costs associated with manufacturing and commercializing the product.

ABOUT LYGENESIS INC.

LyGenesis is a clinical-stage biotechnology company whose cell therapies use patients’ lymph nodes as bioreactors to regrow functioning ectopic organs. LyGenesis’s lead allogeneic cell therapy program is currently in a Phase 2a clinical trial for patients with end stage liver disease (ClinicalTrials.gov Identifier: NCT04496479). LyGenesis’s drug development pipeline includes cell therapies that can produce an ectopic thymus (for aging and multiple other potential indications), pancreas (for Type 1 diabetes), and kidney (for end stage renal disease). Privately held with investment support from Prime Movers Lab and Juvenescence, and other investors, LyGenesis is headquartered in Pittsburgh, Pennsylvania. To learn more, please visit lygenesis.com.

ABOUT PRIME MOVERS LAB

Prime Movers Lab invests in breakthrough scientific startups founded by Prime Movers, the inventors who transform billions of lives. We invest in companies reinventing energy, transportation, infrastructure, manufacturing, agriculture, and human augmentation. Portfolio investments span in-space transportation, industrial solar heat, ag tech, neurotechnology, nano-structured materials, wafer slicing, prosthetics, 3D printing, mobility, longevity, drug discovery, and quantum computers. Learn more at www.primemoverslab.com.

ABOUT JUVENESCENCE

Juvenescence is a life sciences company developing therapies to modify aging and increase healthy human lifespan. It was founded by Jim Mellon, Dr. Greg Bailey, and Dr. Declan Doogan. The Juvenescence team consists of highly experienced drug developers, entrepreneurs, marketers, and investors with a significant history of success in pharmaceutical drug development, synthetic biology, and tissue and cellular engineering.

Juvenescence has a broad portfolio of products in development and is driving innovation, with a focus on discovering and developing these therapies to modify the aging process, through prevention and by regenerating damage, to support healthy aging and increase health span. The company is committed to inspiring and equipping the world to, not just reimagine what it means to age, but to help people Reimagine a Lifetime. For more information see: www.JuvLabs.com.

SOURCE LyGenesis, Inc.

AUSTIN, Texas, Oct. 24, 2023 — QuoteWell, a tech-enabled commercial insurance wholesale brokerage that is at the forefront of innovating the distribution side of insurance, today announced the launch of its brokerage operations to serve independent retail agents. QuoteWell helps agents who are often overlooked and given poor customer service due to low premiums associated with their accounts and provides best-in-class in-house brokers to efficiently find and place the risk.

In the lead-up to today’s public launch, QuoteWell, founded in 2021, has secured over $15 million in Series A funding led by New Enterprise Associates, Inc. (NEA). Goldcrest and Floating Point also participated in the round. The new capital will be used towards expanding the company’s brokerage team and enhancing the infrastructure that underpins automation and operational efficiencies.

“We see a huge opportunity to better serve a segment of the insurance business that is often underserved by incumbents and developed what we call a hybrid insurtech that aims to provide the best service and results for our customers,” said Joey Bouchard, CEO and Founder, QuoteWell. “As a part ‘software startup focused on the insurance sector’ and part ‘wholesale broker,’ we combine industry best practices with a forward-looking, innovative lens to deliver the most impact.”

According to AM Best, the U.S. market alone is set to process over $100B in surplus line premiums in 2023, the segment of insurance that wholesale brokers specialize. Over the past decade, there has been heavy consolidation in the space, and while wholesalers serve various sizes of agents, from mom-and-pop shops to publicly traded companies, many are instructed to focus on accounts that bring in $25,000 in premiums or more. Additionally, insurance carriers often see risk in having their distribution heavily concentrated across a small number of wholesale brokers.

QuoteWell leverages a semi-automated approach to servicing its customers by combining human capital and technology. To date, the company has hired 12 licensed brokers to support submission flow and uses AI-backed models to assist in coverage recommendations from its panel of over 45 carrier partners. As a result, QuoteWell’s brokers can recommend coverage quickly and respond to agents in less than two hours.

“We are excited to partner with QuoteWell as they lead progressive change in a growing market of the insurance industry,” said Rick Yang, Partner and Head of Technology, NEA. “We believe Joey and the QuoteWell team have proven the value of and opportunity in marrying human relationships with automated systems, data and software for best-in-class outcomes. Innovation is critical and QuoteWell is driving efficiency and advancing processes and results for an important corner of an essential industry.”

About QuoteWell
QuoteWell is a tech-enabled commercial insurance wholesale brokerage. The company utilizes AI-backed technology in its submission and marketing processes, empowering best-in-class in-house brokers to efficiently find and place the risk while delivering a responsive and transparent experience for retail agents. QuoteWell has been featured on Fintech Global’s InsurTech 100 List in 2023. The company is headquartered in Austin, Texas, and has raised over $20M from VCs, including NEA, Goldcrest and Floating Point. For more information, please visit www.quotewell.com.

QuoteWell Contact:
Katarina Pregelj
[email protected]

About NEA
New Enterprise Associates, Inc. (NEA) is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. Founded in 1977, NEA has over $25 billion in assets under management, as of March 31, 2023, and invests in technology and healthcare companies at all stages in a company’s lifecycle, from seed stage through IPO. The firm’s long track record of investing includes more than 270 portfolio company IPOs and more than 450 mergers and acquisitions. For more information, please visit www.nea.com.

Contact:
Erica Sunkin
[email protected]

SOURCE NEA

CHICAGO, Oct. 24, 2023 — Thirteen Castles, a technology focused investment firm, announced today that it has agreed to lead an equity investment and establish a technology partnership to build the second phase of hostU’s marketplace. hostU, a medium-term rental platform curated for university students and faculty, was launched out of Northwestern University’s Entrepreneurship center, The Garage.

Thirteen Castles’ investment enables hostU to accelerate the development of its technology stack and strategically expand its marketplace throughout the United States and Europe. “hostU is in a unique position to create the leading marketplace to address the transitory nature of university students in a more and more connected world,” said Thirteen Partners Founder and Managing Partner, Edwin Marcial. “The combination of a visionary founder, an innovative service-orientated approach, and a balanced marketplace of guests and hosts, made it a clear place where we wanted to dedicate our time and resources.”

“Adding Edwin as an Advisory Board member and having his team help us develop the next phase of hostU’s marketplace and matching algorithm may represent the most important milestones we’ve achieved as a company,” said Bella Le Sage, Founder and CEO of hostU. “Edwin’s experience in building the world’s most innovative marketplaces, from Intercontinental Exchange (that now owns the New York Stock Exchange) to SnapNurse, will help hostU provide an unparalleled curated, verified, and simplified service for our guests and hosts.”

About hostU

hostU (www.joinhostu.com) is a platform that facilitates medium-term shared housing rentals within the university community, connecting students and faculty in need of housing with those looking to sublet their space. A matching algorithm verifies university-affiliation and sends users direct matches based on preferences and needs. Once connected, guests and hosts can communicate and make arrangements through the platform.

About Thirteen Castles

Thirteen Castles is a technology focused investment firm focused on marketplace companies.  Thirteen Castles was founded by Edwin Marcial, the former Chief Technology Officer of Intercontinental Exchange (NYSE: ICE). Thirteen Castles’ approach is to provide both capital investment and a technology development team experienced in creating the world’s best marketplaces. 

Media Contact:
[email protected] 

SOURCE hostU

NORWALK, Connecticut, 24 października 2023 r. — spółka venture capital LifeSpan Vision Ventures ogłosiła dzisiaj inwestycję w Matter Bio – spółkę holdingową zajmującą się badanami nad długowiecznością, której działalność skupia się na zachowaniu integralności genomu. U podstaw jej filozofii leży przekonanie, że z wiekiem nasz genom cały czas ulega uszkodzeniom przez czynniki egzo- i endogenne. Pojawiające się od czasu do czasu błędy w genomie umykają i zostają włączone do DNA w formie mutacji, wariacji strukturalnych, zmian epigenetycznych oraz innych form utraty informacji. Matter Bio zbudowała światowej klasy zespół naukowców i menedżerów z myślą o przeciwdziałaniu zjawisku utraty informacji w genomie. W tym celu firma przyjęła model hub & spoke, który pozwala jej osiągać różne przełomy naukowe stanowiące odpowiedź na kluczowe aspekty tego zjawiska. Aktualnie Matter Bio zarządza trzema spółkami oraz dysponuje zapleczem w dziedzinie inkubacji.

„Matter Bio kontynuuje realizację programów komercyjnych, klinicznych oraz badawczych, a środki zainwestowane przez Lifespan Vision Venture przysłużą się do rozwoju jej portfolio, a tym samym osiągnięcia kluczowych kamieni milowych w segmencie naukowym i komercyjnym” – powiedział Chris Bradley, dyrektor generalny Matter Bio.

Zgodnie z założeniami Matter Bio ma rozpocząć badania kliniczne w ramach jednego z programów w ciągu kolejnych 12 miesięcy, a ponadto rozszerzyć przynoszący już przychody program w dziedzinie odczytu sekwencji mutacji z pojedynczej cząsteczki DNA.

Oświadczenie dr Jordana B. Burtona, analityka naukowego w LifeSpan Vision Ventures: „Inwestycja w Matter Bio wpisuje się w naszą misję wspierania firm zajmujących się badaniami nad długowiecznością i tworzeniem rozwiązań spowalniających działanie kluczowych czynników starzenia się organizmu. Opierając się na połączeniu wiedzy naukowej, wydajności i skali działań, stosowany przez nią model biznesowy pozwala realizować cele w zakresie kwantyfikacji i rewersji uszkodzeń DNA z myślą o zapobieganiu chorobom związanym ze starzeniem się organizmu oraz zwiększaniu długości życia w zdrowiu. Cieszymy się na współpracę z tak utalentowanym zespołem pionierów w dziedzinie genetyki i liczymy na to, że nasza współpraca przyczyni się do wydłużenia długości życia poprzez rozwiązania przeciwdziałające zjawisku utraty kluczowych informacji w genomie”.

Matter Bio

Matter Bio to spółka holdingowa założona przez światowej klasy naukowców, w tym dr George’a Churcha i dr Jana Vijga, której celem jest osiąganie naukowych przełomów stanowiących odpowiedź na kluczowe aspekty zjawiska utraty informacji w genomie. Jej główny potencjał stanowią możliwości w zakresie precyzyjnego odczytu sekwencji mutacji, rewersji mutacji somatycznych oraz oczyszczania komórek patologicznych, w tym komórek rakowych.

Więcej informacji można znaleźć na stronie  https://matterbio.com/ .

LifeSpan Vision Ventures

LifeSpan Vision Ventures jest innowacyjną spółką venture capital, która specjalizuje się w inwestycjach w dziedzinie badań nad starzeniem się i długowiecznością. Misją spółki jest wspieranie i przyspieszanie rozwoju innowacyjnych terapii, które wydłużają życie, poprawiają jakość życia osób starzejących się oraz mierzą się z wyzwaniami związanymi z wiekiem. Dzięki strategicznym partnerstwom i inwestycjom spółka chce kształtować przyszłość, w której starzenie się oznacza witalność, odporność i nieskończone możliwości.

Więcej informacji na temat LifeSpan Vision Ventures można znaleźć na stronie https://www.lifespanvisionventures.com/ .

Zdjęcie – https://mma.prnewswire.com/media/2254743/matter_bioworks514x386.jpg

KONTAKT:

Harry Robb

tel.: +44 7795042764

e-mail: harry.robb@lifespanvision.com

SOURCE LifeSpan Vision Ventures

NEW YORK, Oct. 24, 2023 — OrbiMed, a global healthcare investment firm, is pleased to announce it has raised more than $4.3 billion in commitments for its latest private investment funds, including OrbiMed Private Investments IX, OrbiMed Asia Partners V and OrbiMed Royalty & Credit Opportunities IV. 

Consistent with their predecessors, these new funds enable OrbiMed to invest globally, from seed stage for start-ups incubated by OrbiMed through growth capital opportunities. OrbiMed works closely with its portfolio companies to provide tailored financing solutions, which can include equity, credit and royalty-based financing. OrbiMed focuses on innovative and growth-oriented opportunities across healthcare sub-sectors, including biopharmaceuticals, medical devices, diagnostics and technology-enabled healthcare services. 

OrbiMed is led by its 21 partners, with a growing team exceeding 130 professionals that contribute diverse, complementary skills across company incubation, strategy, operations and finance. The firm’s professionals are based in a dozen global locations across key healthcare markets in North America, Europe and Asia.

Investors in these new funds include a broad range of medical institutions, university endowments, foundations, pension funds, sovereign wealth funds and family offices. 

“OrbiMed is deeply appreciative of the continued support we’ve received from many long-standing partners who’ve invested in these funds,” said Carter Neild, a Managing Partner of OrbiMed. “We will endeavor to meet our partners’ high expectations in the coming years.”

About OrbiMed
OrbiMed is a leading healthcare investment firm with more than $17 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies. OrbiMed’s team of more than 130 professionals is based in New York City; London; San Francisco; Shanghai; Hong Kong; Mumbai, India; Herzliya, Israel; and other key global markets. For more information, please visit www.orbimed.com. Follow us on X (formerly Twitter) @OrbiMed.

Media Contact:
Carter Neild, CFA 
Phone: (212) 739.6400 
Email: [email protected]

Erin Bocherer 
Phone: (678) 294-2258
Cogenta Communications for OrbiMed
Email: [email protected]

Logo – https://mma.prnewswire.com/media/2251647/OrbiMed_Logo.jpg 

SOURCE OrbiMed

NEW YORK, 24. Oktober 2023  — OrbiMed, ein globales Investmentunternehmen für das Gesundheitswesen, freut sich bekannt zu geben, dass es mehr als 4,3 Milliarden Dollar an Zusagen für ihre neuesten privaten Investmentfonds, einschließlich OrbiMed Private Investments IX, OrbiMed Asia Partners V und OrbiMed Royalty & Credit Opportunities IV, erhalten hat. 

Wie ihre Vorgänger ermöglichen es diese neuen Fonds OrbiMed, weltweit zu investieren, von der Seed-Phase für Start-ups, die von OrbiMed ins Leben gerufen wurden, bis hin zu Wachstumskapitalmöglichkeiten. OrbiMed arbeitet eng mit seinen Portfoliogesellschaften zusammen, um maßgeschneiderte Finanzierungslösungen anzubieten, die Eigenkapital-, Kredit- und lizenzgebührenbasierte Finanzierungen umfassen können. OrbiMed konzentriert sich auf innovative und wachstumsorientierte Möglichkeiten in allen Teilsektoren des Gesundheitswesens, einschließlich Biopharmazeutika, Medizinprodukte, Diagnostika und technologiegestützte Gesundheitsdienstleistungen. 

OrbiMed wird von seinen 21 Partnern geleitet und verfügt über ein wachsendes Team von mehr als 130 Fachleuten, die unterschiedliche, sich ergänzende Fähigkeiten in den Bereichen Unternehmensinkubation, Strategie, Betrieb und Finanzen einbringen. Die Fachleute des Unternehmens sind an einem Dutzend globaler Standorte in den wichtigsten Gesundheitsmärkten in Nordamerika, Europa und Asien tätig.

Zu den Investoren dieser neuen Fonds gehört ein breites Spektrum von medizinischen Einrichtungen, Universitätsstiftungen, Stiftungen, Pensionsfonds, Staatsfonds und Family Offices. 

„OrbiMed ist sehr dankbar für die kontinuierliche Unterstützung, die wir von vielen langjährigen Partnern erhalten haben, die in diese Fonds investiert haben”, sagte Carter Neild, ein geschäftsführender Partner von OrbiMed. „Wir sind bestrebt darin, die hohen Erwartungen unserer Partner in den kommenden Jahren zu erfüllen.”

Informationen zu OrbiMed
OrbiMed ist ein führendes Investmentunternehmen im Gesundheitswesen mit einem verwalteten Vermögen von mehr als 17 Milliarden US-Dollar. OrbiMed investiert weltweit in der gesamten Gesundheitsbranche, von Start-ups bis hin zu großen multinationalen Unternehmen, über eine Reihe von Private-Equity-Fonds, Public-Equity-Fonds und Lizenzgebühren/Kreditfonds. OrbiMed ist bestrebt, ein bevorzugter Kapitalgeber zu sein, der maßgeschneiderte Finanzierungslösungen und umfangreiche globale Teamressourcen bereitstellt, um den Aufbau von erstklassigen Gesundheitsunternehmen zu unterstützen. Das Team von OrbiMed besteht aus mehr als 130 Fachleuten, die in New York City, London, San Francisco, Shanghai, Hongkong, Mumbai (Indien), Herzliya (Israel) und anderen globalen Schlüsselmärkten tätig sind. Weitere Informationen finden Sie auf www.orbimed.com. Folgen Sie uns auf X (ehemals Twitter) @OrbiMed.

Medienkontakt: 
Carter Neild, CFA 
Tel.: (212) 739.6400 
E-Mail: [email protected]

Erin Bocherer 
Telefon: (678) 294-2258
Cogenta Communications für OrbiMed
E-Mail: [email protected]

Logo – https://mma.prnewswire.com/media/2251647/OrbiMed_Logo.jpg

SOURCE OrbiMed

NORWALK, Connecticut, 23 de octubre de 2023 — LifeSpan Vision Ventures anunció hoy una inversión en Matter Bio, una sociedad de cartera de larga duración cuyo objetivo es preservar la integridad genómica. La filosofía de la empresa es que, a medida que envejecemos, nuestro genoma es constantemente dañado por factores tanto exógenos como endógenos. De manera ocasional, los errores se pierden y se incorporan al ADN en forma de mutaciones, variaciones estructurales, desviación epigenética y otros tipos de pérdida de información. Matter Bio ha reunido a un equipo de científicos y ejecutivos de clase mundial para ayudar a contrarrestar esta pérdida fundamental de información en el genoma. Con este objetivo, la empresa ha adoptado un modelo Spoke-hub para progresar en múltiples avances científicos, cada uno de los cuales interviene en coyunturas críticas de pérdida de información. Hasta la fecha, Matter Bio gestiona tres empresas, además de otras oportunidades de incubación.

“Matter Bio sigue avanzando en sus programas comerciales, clínicos y de investigación, y los frutos de la inversión de Lifespan Vision Venture contribuirán al avance de la cartera de la empresa hacia hitos científicos y comerciales clave”, afirmó Chris Bradley, Director Ejecutivo de Matter Bio.

Matter Bio espera iniciar ensayos clínicos para uno de sus programas en los próximos 12 meses, y ampliar un programa que ya genera ingresos en el espacio de secuenciación de mutaciones de una sola molécula.

El Dr. Jordan B. Burton, analista científico de LifeSpan Vision Ventures, afirmó: “La inversión en Matter Bio impulsa nuestra misión de apoyar a las empresas dedicadas a la longevidad y ralentizar los impulsores clave del envejecimiento. El modelo de negocio de la empresa aporta experiencia académica, eficiencia y escala para cumplir con la misión de cuantificar e invertir el daño al ADN para prevenir enfermedades del envejecimiento y aumentar la vida útil saludable. Nos entusiasma trabajar con un equipo tan talentoso de pioneros en el campo genómico y ansiamos ver cómo la empresa puede ampliar el período de salud para contrarrestar la pérdida crítica de información en el genoma”.

Acerca de Matter Bio
Matter Bio, cofundada con científicos de clase mundial, incluidos los Dres.George Church y Jan Vijg, es una sociedad de cartera que está progresando en múltiples avances científicos, cada uno de los cuales apunta a una coyuntura crítica de pérdida de información. Sus activos centrales incluyen la secuenciación precisa de mutaciones, la reversión de mutaciones somáticas y la eliminación de células patológicas, incluido el cáncer.

Para obtener más información, visite https://matterbio.com/.

Acerca de LifeSpan Vision Ventures
LifeSpan Vision Ventures es una firma de capital de riesgo con visión de futuro que se especializa en inversiones en el campo del envejecimiento y la longevidad. Nuestra misión es apoyar y acelerar el desarrollo de terapias innovadoras que amplíen la vida útil saludable, mejoren la calidad de vida de las personas a medida que envejecen y aborden los desafíos relacionados con la edad. Mediante alianzas e inversiones estratégicas, nuestro objetivo es dar forma a un futuro en el que el envejecimiento se pueda vivir con resiliencia, vitalidad e infinitas posibilidades.

Para obtener más información sobre LifeSpan Vision Ventures, visite https://www.lifespanvisionventures.com/.

CONTACTO: Harry Robb  
Celular: +44 7795042764
harry.robb@lifespanvision.com 

Fotografía: https://mma.prnewswire.com/media/2255166/matter_bioworks514x386.jpg 

FUENTE LifeSpan Vision Ventures

SOURCE LifeSpan Vision Ventures

NORWALK, Conn., 24. Oktober 2023 — LifeSpan Vision Ventures gab heute eine Investition in Matter Bio bekannt, eine Holdinggesellschaft für Langlebigkeit, die sich auf die Erhaltung der Integrität des Genoms konzentriert. Im Mittelpunkt der Unternehmensphilosophie steht die Erkenntnis, dass unser Genom mit zunehmendem Alter ständig durch exogene und endogene Quellen geschädigt wird. Gelegentlich werden Fehler übersehen und in Form von Mutationen, strukturellen Variationen, epigenetischer Drift und anderen Arten von Informationsverlusten in die DNA eingebaut. Matter Bio hat ein Weltklasse-Team von Wissenschaftlern und Führungskräften zusammengestellt, um diesem kritischen Informationsverlust im Genom entgegenzuwirken. Um dies zu erreichen, hat das Unternehmen ein Hub-and-Spoke-Modell gewählt, um mehrere wissenschaftliche Durchbrüche voranzutreiben, die jeweils an kritischen Punkten des Informationsverlustes ansetzen. Bis heute hat Matter Bio drei Unternehmen unter seiner Leitung, weitere befinden sich in der Inkubationsphase.

„Matter Bio treibt seine kommerziellen, klinischen und Forschungsprogramme weiter voran, und die Erlöse aus der Investition von Lifespan Vision Venture werden die Weiterentwicklung des Unternehmensportfolios in Richtung wichtiger wissenschaftlicher und kommerzieller Meilensteine unterstützen”, sagte Chris Bradley, CEO von Matter Bio.

Matter Bio rechnet damit, in den nächsten 12 Monaten klinische Studien für eines seiner Programme zu beginnen sowie ein bereits umsatzstarkes Programm im Bereich der Einzelmolekül-Mutationssequenzierung zu erweitern.

Dr. med. Jordan B. Burton, wissenschaftlicher Analyst bei LifeSpan Vision Ventures, erklärte: „Unsere Investition in Matter Bio unterstreicht unsere Mission, Unternehmen zu unterstützen, die sich der Langlebigkeit und der Verlangsamung der wichtigsten Faktoren des Alterns widmen. Das Geschäftsmodell des Unternehmens vereint akademische Expertise, Effizienz und Skalierbarkeit, um die Mission zu verfolgen, DNA-Schäden zu quantifizieren und rückgängig zu machen, um Alterskrankheiten vorzubeugen und eine gesunde Lebensspanne zu verlängern. Wir freuen uns, mit einem so talentierten Team von Pionieren auf dem Gebiet der Genomik zusammenzuarbeiten und sind gespannt darauf, wie das Unternehmen die Gesundheit verlängern und dem kritischen Informationsverlust im Genom entgegenwirken kann.”

Informationen zu Matter Bio
Matter Bio wurde gemeinsam mit Weltklasse-Wissenschaftlern wie George Church PhD. und Jan Vijg PhD. gegründet und ist eine Holdinggesellschaft, die mehrere wissenschaftliche Durchbrüche vorantreibt, die jeweils auf einen kritischen Punkt des Informationsverlustes abzielen. Zu den Kernkompetenzen des Unternehmens gehören die genaue Sequenzierung von Mutationen, die Umkehrung von somatischen Mutationen und die Beseitigung von pathologischen Zellen, einschließlich Krebs.

Weitere Informationen finden Sie auf https://matterbio.com/.

Informationen zu LifeSpan Vision Ventures
LifeSpan Vision Ventures ist ein zukunftsorientiertes Risikokapitalunternehmen, das sich auf Investitionen im Bereich der Alterung und Langlebigkeit spezialisiert hat. Unser Ziel ist es, die Entwicklung innovativer Therapien zu unterstützen und zu beschleunigen, die die Lebenserwartung verlängern, die Lebensqualität im Alter verbessern und altersbedingte Herausforderungen angehen. Durch strategische Partnerschaften und Investitionen wollen wir eine Zukunft gestalten, in der das Altern mit Vitalität, Widerstandsfähigkeit und unendlichen Möglichkeiten einhergeht.

Weitere Informationen über LifeSpan Vision Ventures finden Sie auf https://www.lifespanvisionventures.com/.

KONTAKT: Harry Robb
Handy: +44 7795042764
harry.robb@lifespanvision.com

Foto – https://mma.prnewswire.com/media/2254743/matter_bioworks514x386.jpg 

SOURCE LifeSpan Vision Ventures

NORWALK, Connecticut, 23 de outubro de 2023 – A LifeSpan Vision Ventures anunciou hoje um investimento na Matter Bio, uma holding de longevidade focada na preservação da integridade do genoma. Um aspecto central para a filosofia da empresa é que, à medida que envelhecemos, nosso genoma está sendo constantemente danificado por fontes exógenas e endógenas. Ocasionalmente, erros passam e são incorporados ao DNA na forma de mutações, variações estruturais, desvio epigenético e outros tipos de perda de informações. A Matter Bio reuniu uma equipe de cientistas e executivos de classe mundial para ajudar a combater essa perda crítica de informações no genoma. Para isso, a empresa adotou um modelo hub-and-spoke para promover vários avanços científicos que intervém em momentos críticos da perda de informações. Até o momento, a Matter Bio tem três empresas sob sua gestão, com outras oportunidades de incubação.

“A Matter Bio continua progredindo seus programas comerciais, clínicos e de pesquisa, e os lucros do investimento da Lifespan Vision Venture apoiarão o avanço do portfólio da empresa em direção aos principais marcos científicos e comerciais”, disse Chris Bradley, CEO da Matter Bio.

A Matter Bio espera iniciar estudos clínicos para um de seus programas nos próximos 12 meses, bem como ampliar um programa de geração de receita no espaço de sequenciamento de mutações de molécula única.

O Dr. Jordan B. Burton, analista científico da LifeSpan Vision Ventures, declarou: “Nosso investimento na Matter Bio promove nossa missão de apoiar empresas dedicadas à longevidade e retardar os principais impulsionadores do envelhecimento. O modelo de negócios da empresa traz experiência acadêmica, eficiência e escala na busca por quantificar e reverter os danos ao DNA na prevenção de doenças do envelhecimento e aumento da vida útil saudável. Estamos entusiasmados em trabalhar com uma equipe tão talentosa de pioneiros no espaço genômico e esperamos ver como a empresa pode ampliar o tempo de vida lutando contra a perda de informações críticas no genoma”.

Sobre a Matter Bio
A Matter Bio, cofundada com cientistas de classe mundial, incluindo George Church PhD. e Jan Vijg PhD., é uma holding que está avançando em várias inovações científicas, cada uma visando uma conjuntura crítica de perda de informações. Seus ativos principais incluem sequenciamento preciso de mutações, reversão de mutações somáticas e eliminação de células patológicas, incluindo câncer.

Para mais informações, acesse https://matterbio.com/.

Sobre a LifeSpan Vision Ventures
A LifeSpan Vision Ventures é uma empresa de capital de risco com visão de futuro especializada em investimentos no espaço de envelhecimento e longevidade. Nossa missão é apoiar e acelerar o desenvolvimento de terapias inovadoras que prolonguem o tempo de vida, melhorem a qualidade de vida dos indivíduos à medida que envelhecem e abordam os desafios relacionados à idade. Por meio de parcerias estratégicas e investimentos, nosso objetivo é moldar um futuro em que o envelhecimento seja recebido com vitalidade, resiliência e possibilidades infinitas.

Para mais informações sobre a LifeSpan Vision Ventures, acesse https://www.lifespanvisionventures.com/.

CONTATO: Harry Robb
Cel.: +44 7795042764
harry.robb@lifeespionvision.com

Foto – https://mma.prnewswire.com/media/2255165/matter_bioworks514x386.jpg  

FONTE LifeSpan Vision Ventures

SOURCE LifeSpan Vision Ventures